Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic NK Cell Therapy for COVID-19
NCT04344548Phase 2Withdrawn
- Sponsor
- Universidad Nacional de Colombia
- Start
- Mar 2020
- Primary completion
- Jun 2020
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of AlloNK in coronavirus disease 2019 (COVID-19), sponsored by Universidad Nacional de Colombia. Planned start Mar 2020; status: withdrawn.
02
Drugs
AlloNK
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04344548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04344548.